Thus, it is hypothesized that dual inhibition of both the VEGF- and FGF-driven pathways, and downstream mTOR pathways, using the combination of lenvatinib plus everolimus, may contribute to the enhanced inhibition of both angiogenic and proliferation pathways in RCC [12,15]. Here, MTOR is linked to renal cell carcinoma.